To make sure you never miss out on your favourite NEW stories, we're happy to send you some reminders

Click 'OK' then 'Allow' to enable notifications

Another Covid-19 Vaccine Shows Almost 95 Percent Protection, Early Data Shows

Another Covid-19 Vaccine Shows Almost 95 Percent Protection, Early Data Shows

US company Moderna say it's a 'great day'

Claire Reid

Claire Reid

A second Covid-19 vaccine is almost 95 percent effective at protecting people from contracting the virus, early data shows.

US company Moderna has shared early research for its vaccine and says it's a 'great day'.

At this point, the UK has not pre-ordered any of this particular vaccine and is still in negotiations with Moderna.


The announcement comes a week after Pfizer shared promising results about its vaccine - stating it was more than 90 percent effective.

Moderna has said it plans to apply to get approval to use the vaccine in the next few weeks, following the successful trial.

According to the BBC, the trial involved 30,000 people, with half being given two doses of the vaccine - four weeks apart. The other half had the placebo.

The analysis looked at the first 95 people to develop Covid-19 symptoms.

It found that only five out of the 95 cases came from people who had had two doses of the vaccine with the other 90 cases occurring in people who had been given the dummy vaccine.

The company has said its vaccine is 94.5 percent effective.

Moderna also said 11 of the cases were 'severe' but none of those were in the people that had been given the vaccine.

Tal Zaks, the chief medical officer at Moderna, told BBC News: "The overall effectiveness has been remarkable... it's a great day."


The company still does not know how long immunity will last - as volunteers of any of the vaccine trials will have to be followed and observed for a longer period of time before any data can be gathered.

Last week, Pfizer and BioNTech announced the results from their vaccine's trial and said it could be available for use by the end of the year.

According to the firms, the jab has been tested out on 43,500 people in six countries, with no safety concerns detected - and only 94 people in the trial went on to develop Covid-19.

The companies are now planning on applying for emergency approval to roll the vaccine out by the end of the month.

Featured Image Credit: PA

Topics: Science, US News